Galectin Therapeutics GALTW 深 沪
已收盘 10-08 16:00:00 美东时间
0.0425
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0425
- 总市值 0
- 52周最高 0.254
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.024
- 委 比 0.00%
- 总股本 --
- 历史最高 0.254
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.024
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt wil
01-22 06:01
Galectin Advances Belapectin Program, Secures New Insider Financing
Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, G...
2025-12-19 21:14
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.
2025-12-17 20:44
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Galectin Therapeutics ( ($GALT) ) just unveiled an announcement. On December 3,...
2025-12-04 01:28
Galectin Therapeutics GAAP EPS of -$0.13
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.13. More on Galectin Therapeutics Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program Seeking Alpha’s Quant Ratin...
2025-11-14 21:10
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
The Phase 2 NAVIGATE trial demonstrates that belapectin 2 mg/kg consistently reduces liver stiffness, new variceal development, and improves biomarkers in patients with compensated MASH cirrhosis and portal hypertension, with significant antifibrotic and disease-modifying potential.
2025-11-10 13:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
2025-09-16 05:06
Galectin Therapeutics Highlights Promising Belapectin Results
An update from Galectin Therapeutics ( ($GALT) ) is now available. On September...
2025-09-08 20:21
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.
2025-08-14 23:51
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from
2025-08-14 20:09
